Mercury Ev-techMERCURYEV | Dealer Network Expansion and GEDA Subsidy Eligibility for EV Products11 Sept 2026Regulatory Product Approval×2 | -1.2% -6.8% — | ₹37.8 | 718 Cr | 290.8 | 2.1% | +47.9% |
Acutaas ChemicalsPharmaceuticals | Acutaas Chemicals gets patent for 2,4-Dimethylthiophenol process, total patents now 1110 Sept 2026Regulatory Product Approval×2 | -5.6% -5.5% — | ₹3,174 | 25,984 Cr | 67.3vs 32.0 | 27.5% | +59.1% |
Sterlite TechnologiesSTLTECH | STL launches plenum-rated fiber trunk assemblies for AI data centers10 Sept 2026Regulatory Product Approval | -0.6% +0.7% — | ₹1,019 | 49,931 Cr | 205.0 | 3.0% | +87.4% |
Sigma Advanced SystemSIGMAADV | Sigma Advanced Systems starts production at Sri City aerospace facility10 Sept 2026Regulatory Product Approval | +10.3% +25.8% — | ₹1,092 | 19,352 Cr | 118.2 | 49.5% | — |
Gennex LaboratoriesPharmaceuticals | Subsidiary Deccan Remedies gets drug licence for 6 new products8 Sept 2026Regulatory Product Approval | -3.3% -10.9% — | ₹9.99 | 243 Cr | 12.3vs 32.0 | 8.4% | +51.2% |
Bandhan BankPrivate Sector Bank | Bandhan Bank clarifies on credit card launch news, no undisclosed info8 Sept 2026Regulatory Product Approval | +1.4% +4.2% — | ₹163 | 26,259 Cr | 19.4vs 12.1 | — | — |
South West PinnacleDiversified Commercial Services | Geological Report vetted for Jogeshwar coal mine, submitted to Ministry of Coal7 Sept 2026Regulatory Product Approval | +8.3% -5.9% -8.6% | ₹194 | 578 Cr | 14.5vs 13.9 | 18.6% | +53.4% |
Rhetan TMTIron & Steel Products | Rhetan TMT explores entry into Corrosion Resistant Steel TMT Bars market5 Sept 2026Regulatory Product Approval×2 | +10.2% -19.0% -31.5% | ₹17.41 | 1,387 Cr | 67.0vs 17.0 | 9.7% | -19.3% |
Titan IntechIT Enabled Services | Titan Intech gets OEM recognition on GeM platform for display products4 Sept 2026Regulatory Product Approval | -2.0% -1.0% -3.0% | ₹0.94 | 88 Cr | 10.4vs 18.9 | 3.6% | +47.4% |
SPML InfraCivil Construction | SPML Infra develops proprietary 104.4 kWh battery pack, clears global certifications4 Sept 2026Regulatory Product Approval | +4.2% -0.1% -8.8% | ₹159 | 1,408 Cr | 14.5vs 14.6 | 5.0% | +82.3% |
Hybrid Financial ServiceStockbroking & Allied | BSE admits Hybrid Financial Services as Trading Member in Cash Segment2 Sept 2026Regulatory Product Approval | -2.1% -1.1% +2.8% | ₹17.96 | 52 Cr | 16.5vs 15.8 | 3.5% | -15.3% |
Caplin Point LabPharmaceuticals | Caplin Point subsidiary gets GMP certification from Colombia's INVIMA1 Sept 2026Regulatory Product Approval | +4.4% +1.4% -4.7% | ₹2,639 | 20,053 Cr | 30.1vs 32.0 | 21.9% | +19.6% |
L&T FinanceInvestment Company | IRDAI grants Corporate Agent (Composite) registration to L&T Finance1 Sept 2026Regulatory Product Approval | +2.5% -0.1% -14.8% | ₹260 | 65,177 Cr | 20.5vs 20.7 | — | +23.1% |
Gland PharmaPharmaceuticals | USFDA inspection at Visakhapatnam facility closed with zero observations1 Sept 2026Regulatory Product Approval×2 | +0.8% +1.5% +0.6% | ₹3,154 | 52,028 Cr | 46.0vs 32.0 | 13.4% | +19.6% |
Sakar HealthcarePharmaceuticals | Sakar Healthcare gets 14 oncology product approvals in EU, UK and Canada1 Sept 2026Regulatory Product Approval | +14.2% +29.6% +26.0% | ₹1,024 | 2,278 Cr | 63.2vs 32.0 | 10.7% | +38.4% |
NLC IndiaPower Generation | NLC India wins mineral licence for two blocks in Telangana31 Aug 2026Regulatory Product Approval | +3.2% +1.1% -5.3% | ₹250 | 34,687 Cr | 10.4vs 21.2 | 5.4% | +23.3% |
Life Insura Corp of IndiaLife Insurance | LIC launches two new insurance products for domestic market31 Aug 2026Regulatory Product Approval×2 | -1.4% -2.2% -5.2% | ₹385 | — | — | — | — |
Balaxi PharmaBALAXI | Balaxi Pharma receives WHO-GMP certification for Hyderabad facility31 Aug 2026Regulatory Product Approval | +1.0% +3.5% +0.4% | ₹22.42 | 124 Cr | 49.8 | 1.8% | +14.1% |
Suraj IndustriesBreweries & Distilleries | Subsidiary Carya Gets Distillery License in Rajasthan, Ops from September 202627 Aug 2026Regulatory Product Approval | +1.7% -0.8% -6.0% | ₹52.46 | 175 Cr | 25.0vs 26.4 | -1.7% | +405.4% |
Dolat AlgotechStockbroking & Allied | Dolat Algotech gets MCX self-clearing membership approval25 Aug 2026Regulatory Product Approval | -1.4% -5.5% -11.2% | ₹61.9 | 1,089 Cr | 7.6vs 15.8 | 16.0% | +26.9% |
Biocon Limited.Pharmaceuticals | Biocon Biologics gets Japan approval for Pegfilgrastim biosimilar25 Aug 2026Regulatory Product Approval×5 | +2.0% -1.7% -6.6% | ₹360 | 58,669 Cr | 105.9vs 32.0 | 0.9% | +10.0% |
Jubilant PharmovaPharmaceuticals | USFDA approves Line 3 at Spokane contract manufacturing facility23 Aug 2026Regulatory Product Approval | +2.1% +2.6% +21.3% | ₹975 | 15,503 Cr | 43.9vs 32.0 | 4.7% | +17.3% |
Mamata MachineryIndustrial Products | Patent granted for Quadra 600 machine BOPP bag technology21 Aug 2026Regulatory Product Approval | -1.7% -4.7% -4.6% | ₹395 | 972 Cr | 108.8vs 28.8 | 10.1% | -90.6% |
Glenmark PharmaceuticalsPharmaceuticals | Glenmark's US arm launches Calcium Gluconate Injection in US market21 Aug 2026Regulatory Product Approval×4 | +2.5% +5.2% +5.4% | ₹2,293 | 64,711 Cr | 36.0vs 32.0 | 14.7% | +23.1% |
Anant RajResidential Commercial Projects | Anant Raj gets RERA registration for Gurugram luxury housing project20 Aug 2026Regulatory Product Approval | -3.1% -7.5% -6.0% | ₹612 | 22,020 Cr | 37.1vs 21.3 | 10.2% | +6.6% |
Titagarh Rail SystemsRailway Wagons | Vendor approval for 3-Phase Locomotive Traction Motor from Indian Railways19 Aug 2026Regulatory Product Approval | +1.8% -1.5% +1.2% | ₹800 | 10,772 Cr | 56.4 | 7.4% | +12.6% |
Strides Pharma SciPharmaceuticals | Strides gets USFDA clearance for Bengaluru plant19 Aug 2026Regulatory Product Approval | +3.0% +7.7% +28.8% | ₹1,101 | 10,152 Cr | 16.6vs 32.0 | 16.6% | +13.0% |
Iirm Holdings IndiaConsulting Services | Subsidiary gets IRDAI registration as Corporate Agent19 Aug 2026Regulatory Product Approval | -0.2% -2.1% +5.7% | ₹123 | 836 Cr | 34.1vs 8.7 | 14.4% | +8.2% |
Centum ElectronicsAerospace & Defense | ECMS approval for Rs. 106 crore investment in Transducers and Filters18 Aug 2026Regulatory Product Approval | +0.4% -0.1% +37.9% | ₹4,340 | 6,405 Cr | 119.8vs 76.4 | 18.0% | -25.3% |
Permanent MagnetsOther Electrical Equipment | Subsidiary Quantum Magnetics gets ECMS approval for Neodymium magnets18 Aug 2026Regulatory Product Approval | +9.0% +9.3% +3.8% | ₹880 | 757 Cr | 50.2vs 25.4 | 9.3% | +47.0% |
Colgate PalmolivePersonal Care | Colgate PerioGard earns ISP Seal of Acceptance — first in India18 Aug 2026Regulatory Product Approval | +0.4% -3.9% -1.2% | ₹1,763 | 47,954 Cr | 35.6vs 35.6 | 107.1% | +11.8% |
PCBL ChemicalCarbon Black | PCBL gets ECMS approval for Acetylene Black Project worth Rs 329 cr18 Aug 2026Regulatory Product Approval | +2.9% +2.3% +7.0% | ₹327 | 12,865 Cr | 49.2 | 3.4% | +17.0% |
MAN Industries (I)Iron & Steel Products | Man Industries wins PML approval from QatarEnergy for LSAW pipes14 Aug 2026Regulatory Product Approval | +8.0% +22.1% +39.6% | ₹905 | 6,787 Cr | 32.7vs 17.0 | 9.8% | +41.9% |
Prithvi Exchange (India) LimitOther Financial Services | RBI grants Perpetual AD-II License to Prithvi Exchange13 Aug 2026Regulatory Product Approval | -1.0% -5.8% +1.7% | ₹104 | 86 Cr | 30.9vs 20.9 | 6.2% | +29.4% |
FDCPharmaceuticals | FDC subsidiary gets UK MHRA approval for Atropine eye drops13 Aug 2026Regulatory Product Approval | +0.3% -3.0% -1.4% | ₹329 | 5,350 Cr | 18.3vs 32.0 | 14.7% | +3.0% |
WanburyPharmaceuticals | Wanbury gets EDQM nod for Rivaroxaban API, USFDA DMF clearances13 Aug 2026Regulatory Product Approval×2 | -2.0% +0.2% -14.2% | ₹197 | 690 Cr | 14.6vs 32.0 | 12.3% | +24.5% |
Bajaj HealthcarePharmaceuticals | Bajaj Healthcare gets DCGI nod to launch Cenobamate API and Tablets in India12 Aug 2026Regulatory Product Approval | +0.5% -1.8% -1.8% | ₹322 | 1,084 Cr | 59.7vs 32.0 | 4.8% | +11.3% |
Zydus LifesciencesPharmaceuticals | Zydus launches REVAHALE, India's first once-daily nebulised LAMA for COPD10 Aug 2026Regulatory Product Approval×2 | +7.2% -1.0% +0.2% | ₹1,158 | 1.16 L Cr | 25.8vs 32.0 | 18.0% | +22.0% |
MAN InfraResidential Commercial Projects | MICL Group gets IOA for Bandra luxury project with 1000+ crore GDV10 Aug 2026Regulatory Product Approval | -2.2% -3.3% +13.1% | ₹123 | 4,949 Cr | 22.8vs 21.3 | 11.4% | +19.4% |
Astrazeneca Pharma IndPharmaceuticals | AstraZeneca India gets CDSCO nod for Enhertu additional indication8 Aug 2026Regulatory Product Approval×3 | -3.2% -8.5% -16.5% | ₹5,921 | 14,801 Cr | 87.3vs 32.0 | 25.0% | +29.7% |